Tilia Fiduciary Partners Inc. lowered its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,261 shares of the company’s stock after selling 92 shares during the period. Tilia Fiduciary Partners Inc.’s holdings in Johnson & Johnson were worth $540,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also added to or reduced their stakes in JNJ. Moneta Group Investment Advisors LLC raised its stake in shares of Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after acquiring an additional 54,326,454 shares in the last quarter. Norges Bank bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $4,609,399,000. Providence Capital Advisors LLC raised its stake in shares of Johnson & Johnson by 141,974.0% during the first quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock valued at $30,651,000 after acquiring an additional 4,747,612 shares in the last quarter. Morgan Stanley raised its stake in shares of Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after acquiring an additional 4,521,062 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Johnson & Johnson by 15.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after acquiring an additional 3,849,148 shares in the last quarter. Institutional investors own 68.40% of the company’s stock.
Analyst Ratings Changes
Several research firms have recently weighed in on JNJ. TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. Wells Fargo & Company cut their price objective on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a report on Thursday, August 31st. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a report on Thursday, August 31st. Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Finally, Raymond James cut their price objective on shares of Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating on the stock in a report on Tuesday, September 5th. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $170.65.
Insider Activity
In other news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Price Performance
Shares of JNJ opened at $160.50 on Friday. The firm has a market capitalization of $417.13 billion, a PE ratio of 32.49, a price-to-earnings-growth ratio of 3.27 and a beta of 0.54. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04. The company’s fifty day moving average price is $166.51 and its 200-day moving average price is $162.00.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The firm had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.59 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 10.02 EPS for the current year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- What is the NASDAQ Stock Exchange?
- 3 Reasons This Sleeping Giant Is About To Wake Up
- Investing in Agriculture 101: How to Invest in Agriculture
- MarketBeat Week in Review – 9/18 – 9/22
- Insider Trades May Not Tell You What You Think
- 52-week Low Names To Tip The Upside Scale In Your Favor
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
